{
  "id": 12913758,
  "title": "AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias",
  "url": "https://urgent.news/2026/10/08/aviadobio-presents-new-safety-and-biomarker-data-from-the-phase-1-2",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T17:06:17.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/aviadobio-presents-new-safety-and-biomarker-data-from-the-phase-1-2-aspire-ftd-trial-at-the-international-conference-on-frontotemporal-dementias"
  },
  "original_language": "en",
  "account": null,
  "summary": "Evolving biomarker data show early signs of dose-dependent increase in cerebrospinal fluid (CSF) progranulin Serum neurofilament light chain (NfL) at/below baseline in all patients with 52-week data AVB-101 continues to be well tolerated, with no serious adverse events related to treatment to date and no immunosuppression required LONDON — AviadoBio, a pioneering gene therapy company […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}